ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc (LXRX)

1.64
0.02
(1.23%)
Closed September 18 4:00PM
1.69
0.05
( 3.05% )
Pre Market: 8:45AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.69
Bid
1.69
Ask
1.70
Volume
1,959
0.00 Day's Range 0.00
0.92 52 Week Range 3.73
Market Cap
Previous Close
1.64
Open
-
Last Trade
1
@
1.69
Last Trade Time
08:10:26
Financial Volume
-
VWAP
-
Average Volume (3m)
2,775,799
Shares Outstanding
361,492,295
Dividend Yield
-
PE Ratio
-3.35
Earnings Per Share (EPS)
-0.49
Revenue
1.2M
Net Profit
-177.12M

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Lexicon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LXRX. The last closing price for Lexicon Pharmaceuticals was $1.64. Over the last year, Lexicon Pharmaceuticals shares have traded in a share price range of $ 0.92 to $ 3.73.

Lexicon Pharmaceuticals currently has 361,492,295 shares outstanding. The market capitalization of Lexicon Pharmaceuticals is $592.85 million. Lexicon Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.35.

LXRX Latest News

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

THE WOODLANDS, Texas, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeff Wade, president and chief operating officer, has decided to step...

New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes

Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin   TIR measures approach target set by American Diabetes Association Data to be...

Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences

THE WOODLANDS, Texas, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lexicon management will participate in the following investor...

New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration

Results showed reductions in heart attack, stroke and heart failure events in all patients with even greater benefit for heart failure events among patients with longer diabetes duration New...

Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio

Company to Focus on Targeted Promotion of INPEFA® in Heart Failure While Prioritizing Investment in the Potential Launch of ZYNQUISTA™ Efforts Expected to Reduce 2025 Operating Costs by $40...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1001.691.731.617254801.64767892CS
4-0.24-12.43523316061.931.98871.5620882931.70169838CS
12001.692.451.5127757991.84887154CS
26-0.79-31.85483870972.482.591.4827662491.85480523CS
520.4637.39837398371.233.730.9231551111.87569645CS
156-3-63.96588486144.696.32990.9217446632.2015986CS
260-2.12-55.64304461943.819.650.9220231683.10736058CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.1224
(0.00%)
1.75M
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.9381
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.87
(0.00%)
7
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5187
(0.00%)
23
AAGRAfrican Agriculture Holdings Inc
$ 0.1224
(0.00%)
1.75M
AADRAdvisorShares Dorsey Wright ADR ETF
$ 62.9381
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.87
(0.00%)
7
AACIArmada Acquisition Corporation I
$ 9.75
(0.00%)
0
AACGATA Creativity Global
$ 0.5187
(0.00%)
23
FRGTFreight Technologies Inc
$ 0.1239
(0.00%)
45.28M
MAXNMaxeon Solar Technologies Ltd
$ 0.0909
(0.00%)
22.36M
TBIOTelesis Bio Inc
$ 1.36
(0.00%)
16.38M
SQQQProShares UltraPro Short QQQ
$ 8.40
(0.00%)
14.98M
ACHLAchilles Therapeutics PLC
$ 0.71
(0.00%)
13.13M

LXRX Discussion

View Posts
BooDog BooDog 1 week ago
News: New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
September 10, 2024 08:00 ET
| Source: Lexicon Pharmaceuticals, Inc.
Share






Study results aligned with positive clinical trial outcomes for type 1 diabetes treatment with sotagliflozin

TIR measures approach target set by American Diabetes Association

Data to be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online

THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated that once-daily dosing of sotagliflozin 400 mg improved time-in-range (TIR) and several continuous glucose monitoring (CGM) parameters, including glucose variability, in insulin-treated type 2 diabetes (T2D) patients. Researchers also observed positive trends with the once-daily dose of 200 mg. Study findings will be presented September 12th at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain and online.

The objective of the SOTA-INS CGM study was to evaluate the effect of sotagliflozin on TIR as assessed by CGM in people with T2D. The primary sub-study endpoint was mean change in percentage of time spent within TIR (glucose 70-180 mg/dL [3.9-10.0 mmol/L]) over 24 hours for sotagliflozin 400 mg versus placebo.

The American Diabetes Association recommends a TIR target of at least 70% (17 hours) in people with type 1 diabetes (T1D) or T2D. In this study, sotagliflozin 200 mg and 400 mg once daily TIR (15.3 and 15.9 hours, respectively) approached the ADA target, with modest reductions in time-above-range (TAR) and mild increases in time-below-range (TBR).

Sotagliflozin has previously demonstrated glycemic efficacy and improvements in TIR as an adjunct to insulin therapy in people with T1D who participated in the inTandem clinical trial program.


https://www.globenewswire.com/news-release/2024/09/10/2943581/0/en/New-Secondary-Analysis-of-Phase-3-Data-Demonstrates-Sotagliflozin-Improves-Time-In-Range-TIR-and-Several-Parameters-of-Glucose-Control-and-Variability-in-Basal-Insulin-Treated-Type.html
👍️0
Monksdream Monksdream 3 weeks ago
LXRX under $2
👍️0
BooDog BooDog 2 months ago
Back under $2 again, printing 1.70's. Setting up for another swing.
👍️0
Monksdream Monksdream 2 months ago
LXRX under $2
👍️0
BooDog BooDog 2 months ago
Just may be an early Christmas. https://www.globenewswire.com/news-release/2024/07/16/2913701/0/en/Lexicon-Pharmaceuticals-Receives-December-20-2024-PDUFA-Goal-Date-for-Sotagliflozin-Type-1-Diabetes-NDA-Resubmission.html
👍️0
Monksdream Monksdream 2 months ago
LXRX under $2
👍️ 1
jdheart101 jdheart101 4 months ago
Garbage
👍️0
dcaf7 dcaf7 4 months ago
Interesting sales estimates for Sota.
Apr 30, 2024
Leerink initiated coverage of Lexicon with an Outperform rating and $5 price target. The firm believes Lexicon’s first-in-class dual SGLT1/2 inhibitor sotagliflozin could address unmet need across multiple indications with large market opportunities, including heart failure, hypertrophic cardiomyopathy and Type 1 diabetes with chronic kidney disease, which could collectively drive blockbuster sales. Inpefa’s U.S. launch in HF should benefit from several meaningful tailwinds, Leerink says. It forecasts peak U.S. sales of $1B for Inpefa in HF and peak U.S. sales of $325M for sotagliflozin in HCM in FY32. The firm also points out that Lexicon plans to resubmit Zynquista’s NDA filing by mid-2024, with an anticipated 6-month review. Leerink forecasts peak U.S. sales of $225M for Zynquista in T1D with CKD in FY32.
👍️0
BooDog BooDog 5 months ago
Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.
👍️0
BooDog BooDog 5 months ago
Zacks analysis.
https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.
👍️0
BooDog BooDog 6 months ago
Quite the gap there if that's what you're looking at.
👍️0
glenn1919 glenn1919 6 months ago
LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
dcaf7 dcaf7 6 months ago
Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
👍️ 1
Awl416 Awl416 6 months ago
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
👍️0
BooDog BooDog 7 months ago
Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed
👍️0
jdheart101 jdheart101 7 months ago
200 July 2.5 calls @.88 . Be back soon !!!
👍️0
TIMGZ TIMGZ 7 months ago
INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT
👍️0
BooDog BooDog 7 months ago
Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

👍️0
glenn1919 glenn1919 7 months ago
LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
jdheart101 jdheart101 8 months ago
Another 4000. @1.76
👍️0
Legend431 Legend431 8 months ago
Oops
👍️0
jdheart101 jdheart101 8 months ago
I’m in today 9500 @1.49 1/23/24
👍️0
BooDog BooDog 9 months ago
Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/


Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news
👍️0
BooDog BooDog 10 months ago
Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
👍️0
Monksdream Monksdream 10 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 11 months ago
$LXRX. Looking good. See this in a week or 2.

JMHO.
👍️0
glenn1919 glenn1919 11 months ago
LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
TRADER99 TRADER99 11 months ago
Looks like we saw a bottom here with this spike in volume
👍️0
Monksdream Monksdream 12 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 12 months ago
Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers
👍️0
Monksdream Monksdream 12 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 12 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 12 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 1 year ago
LXRX new 52 week low
👍️0
BooDog BooDog 1 year ago
LXRX 1.70's. Watching.
👍️0
BooDog BooDog 1 year ago
$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
👍️0
BooDog BooDog 1 year ago
👍️0
BooDog BooDog 1 year ago
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
👍️0
BooDog BooDog 1 year ago
Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
👍️0
TIMGZ TIMGZ 1 year ago
LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
👍️ 1
BooDog BooDog 1 year ago
2.75 support. See how it holds, or not. Interesting sell off.
👍️0
glenn1919 glenn1919 1 year ago
LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
👍️0
glenn1919 glenn1919 1 year ago
LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
If I se what I think I see, there's a reason shorts are leaving this puppy alone.

Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
👍️0
glenn1919 glenn1919 1 year ago
LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

See what this puppy does.


https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
👍️0
BooDog BooDog 1 year ago
Passing 2.69.
👍️0
BooDog BooDog 1 year ago
Let's get the move on.
👍️0
BooDog BooDog 2 years ago
PUDUFA coming in a couple months. Looks like they're pretty confident.

GLTA
👍️0

Your Recent History

Delayed Upgrade Clock